Investment analysts at Cantor Fitzgerald issued their FY2025 EPS estimates for shares of Capricor Therapeutics in a research ...

Shares of Capricor Therapeutics Inc (NASDAQ:CAPR – Get Free Report) have received an average rating of “Buy” from the six ...

Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shareholders might understandably be very concerned that the share ...

The consensus price target hints at a 208.1% upside potential for Capricor (CAPR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings ...

Capricor Therapeutics has completed its submission of a biologics license application (BLA) seeking U.S. approval of deramiocel, the company’s cell therapy for heart muscle disease in people with ...

Linda Marbán, CEO of cell and exosome-based therapy biotech Capricor Therapeutics, agreed that the industry will be watching closely. And despite the swirling gloom, some of last year’s “cautious ...

Capricor Therapeutics (NASDAQ:CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that ...

On Friday, H.C. Wainwright reaffirmed a Buy rating with a price target of $77.00 on Capricor Therapeutics (NASDAQ:CAPR) shares. The firm's analyst highlighted the completion of a rolling Biologics ...

Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.